Clinical trial
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
NCT02104947 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT02104947 |
|---|---|
| Title | Reversal of Dabigatran Anticoagulant Effect With Idarucizumab |
| Official title | A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hemorrhage |
| Intervention type | Drug |
| Interventions | idarucizumab |
| Enrollment | 503 |
| Start date | May 6, 2014 |
| Primary completion | Jul 25, 2016 |
| Completion | Oct 20, 2016 |
| First posted | Apr 7, 2014 |
| Last update posted | Jan 5, 2018 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, Finland, France, Germany and 21 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: